ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Diabetic Kidney Disease Collaborative (DKD-C)

Working Together to Address the Urgent and Unmet Needs in the Diagnosis and Treatment of People with Diabetic Kidney Disease

Diabetic Kidney Disease Virtual Roundtable Series: 

ASN's DKD-C Task Force is hosting a virtual roundtable series for healthcare providers and individuals with diabetes and kidney disease.  The series includes the following three events.  Register today!

View the webinar:

Management of Diabetes & Kidney Disease through COVID-19

Recorded on Tuesday, Aug 18, 2020

90 minutes

Details the care needs and the patient experience managing diabetes and kidney disease during the COVID-19 pandemic. Outlines frequent patient concerns, and provide strategies for maintaining health.  

Topics presented include:

·         Population Susceptibility To Diabetes

·         Diabetes and Kidney Disease during COVID-19

·         COVID-19 and DKD Management: A Personal Journey

·         Patient Access to New Therapies

·         Coordinating DKD Care: Who Takes Care Of My Diabetes, And Who Takes Care Of My Kidneys?

·         Roundtable Discussion

 

View the webinar:

Goal-Directed Medical Therapies for Patients with Diabetic Kidney Disease

Recorded on Tuesday, Sept 29, 2020
90 minutes

Leading experts in the care of individuals with diabetic kidney disease (DKD) describe the new standard of care for DKD, discuss the clinical indications for SGLT2 inhibitors, and consider payment issues associated with new therapies. The session concludes with a roundtable discussion of key questions, including those submitted by the videoconference participants.  

Topics presented include:

  • What is The Standard of Care for Diabetic Kidney Disease?
  • Safely and Effectively Prescribing SGLT2 Inhibitors
  • Paying for New Therapies
  • DAPA-CKD Study
  • EMPEROR-Reduced Study
  • Roundtable Discussion

 

New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes

Thursday, Dec 10, 2020
4:00 PM - 5:30 PM ET

Clinical experts will review the latest guidelines for both kidney disease and heart disease, and discuss the most recent trials and promising therapies. A roundtable of experts from nephrology, cardiology, and endocrinology will consider implications for diabetes, kidney and heart disease treatment in 2021.  

Topics for presentation and discussion:

·         Evolving Landscape For Diabetic Kidney Disease

·         Kidney Disease Guideline Overview

·         Cardiovascular Disease Guideline Overview

·         Roundtable Discussion

Recording | Slides | Speaker Bios | 
Why Should I Join A Clinical Trial?

Recording Slides | Speaker Bios

Register Here

 

Support of the Diabetic Kidney Disease Collaborative is provided by Bayer, Boehringer Ingelheim and Lilly, AstraZeneca, and Janssen Pharmaceuticals, Inc.DKD-C Supporters



KDIGO Diabetes Management Publication

Kidney Disease: Improving Global Outcomes (KDIGO) is pleased to announce the publication of the 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). The guideline, along with the Executive Summary, is now available online and will be published in the October print version of Supplement to Kidney International.

Topics include comprehensive care, glycemic monitoring and targets, lifestyle and antihyperglycemic interventions, approaches to self-management, and optimal models of care.